The ongoing conflict in the Middle East has sparked concerns about medicine shortages in New Zealand, with pharmacists calling for more transparency from Pharmac. The agency has already listed isosorbide mononitrate, an essential medication for angina, as the first drug facing shipping delays due to the war. This has raised serious concerns among healthcare professionals and patients alike.
Clive Cannons, from the Independent Community Pharmacy Group, emphasizes the critical nature of this medication. He explains that isosorbide mononitrate is a life-saving drug for those suffering from angina, a condition characterized by chest pain due to reduced blood flow to the heart. Cannons highlights the urgency of the situation, stating that pharmacists have been proactive in addressing these concerns by writing to Health New Zealand, but have yet to receive a response.
The lack of communication from Pharmac is a significant issue, according to Cannons. He believes that the agency should have a comprehensive plan in place to address potential supply chain disruptions, similar to the fuel plan implemented by the government. By providing such a plan, Pharmac could alleviate patient concerns and ensure that healthcare professionals are well-informed about potential shortages.
Pharmac's acting director, Claire Pouwels, acknowledges the agency's role in managing supply issues and working closely with the Ministry of Health, Health NZ, and suppliers. She explains that Pharmac regularly addresses around 100 supply issues related to medical devices and medicines each month. When a supply issue is identified, Pharmac creates a management plan, assessing the risk and exploring alternatives such as using other funded medicines or securing supplies from different suppliers.
Pouwels also emphasizes Pharmac's commitment to transparency. The agency maintains an up-to-date website with information about supply issues, including a dedicated page for medicine supply notices. This page provides details about supply issues affected by the conflict and filters relevant information for clinicians, suppliers, and prescribers. Pharmac also welcomes feedback on the provided information, ensuring that the healthcare community stays informed.
However, the lack of proactive communication from Pharmac has been criticized. While the agency is responsive to supply issues, the delay in addressing patient concerns is a cause for worry. The situation highlights the importance of clear and timely communication between healthcare authorities and the public, especially during times of crisis.
In my opinion, the medicine shortage crisis in New Zealand due to the Middle East conflict is a complex issue. It underscores the need for robust supply chain management and transparent communication from Pharmac. While the agency is taking steps to address supply issues, there is room for improvement in terms of proactive communication and community engagement. As an expert commentator, I believe that Pharmac should consider implementing more comprehensive strategies to ensure the uninterrupted supply of essential medications, especially during times of geopolitical tension.
